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 Therapeutic Antibodies in Multiple 
Sclerosis 
 Norbert Goebels    Burkhard Becher 
 Neurologische Klinik, Universitätsspital Zürich,  Zürich , Switzerland 
ment of ever more effective drugs for the treatment of 
MS.
 The first immunomodulatory agents to benefit from 
the development mentioned above, interferon-  (Avon-
ex  , Betaferon/Betaseron  , Rebif  ) and glatiramer ace-
tate (Copaxone  ), have been on the market for more than 
a decade now and are established, safe, yet only mildly ef-
fective treatments for MS. They reduce the frequency of 
new relapses by 30–40%, and their effect on disease pro-
gression has remained controversial. Additionally, the ne-
cessity to self-inject these drugs in intervals between once 
daily (Copaxone  ) to once weekly (Avonex  ), as well as 
common side effects, such as flu-like symptoms and injec-
tion site reactions, limit patient compliance to some de-
gree. Numerous researchers have demonstrated that both 
interferon-  and glatiramer acetate exert ‘pleiotropic ef-
fects’ on the immune system and the CNS, while essen-
tially leaving the question unanswered as to which of these 
multiple modes of action are central in treating MS.
 In contrast, antibodies, in principal a natural compo-
nent of the immune system, constitute a different kind of 
therapeutic agents, which can interact with precisely de-
fined targets. This issue of  Neurodegenerative Diseases fo-
cuses on the role of antibodies as a therapy for MS. The 
article by Soelberg Sorensen is dedicated to a truly ‘natu-
ral’ human antibody preparation: these so-called ‘intra-
venous immunoglobulins’ are polyclonal human anti-
bodies isolated from the pooled plasma of thousands of 
human donors. Intravenous immunoglobulins contain 
the normal humoral immune repertoire and have been 
 Multiple sclerosis (MS) is the most common chronic 
inflammatory disease of the central nervous system 
(CNS). MS commonly strikes young adults, exposing 
them to an uncertain future dimmed by neurological im-
pairment. In spite of immense research efforts in the last 
decades, there is still no cure for MS. In fact, the cause of 
MS, leading to variable degrees of inflammation, demy-
elination and axonal damage in the CNS, is enigmatic. 
While a strong genetic predisposition is established, en-
vironmental factors, possibly infectious agents encoun-
tered during childhood and puberty, seem to play an 
equally important role.
 Until the early 1990s, immunosuppressive agents like 
azathioprine were the mainstay of MS treatment. Since 
then, MS therapy has dramatically changed. New immu-
nobiological findings and pathophysiological concepts as 
well as advances in biotechnology lead to the identifica-
tion of a variety of potential therapeutic targets. Improve-
ments in clinical trial design and the development of 
magnetic resonance imaging have made it possible to ob-
jectively quantify the therapeutic benefit of new treat-
ment modalities in a disease as heterogeneous and unpre-
dictable as MS. Also, both society and health insurances 
have recognized that prevention or delay of neurological 
impairment in MS patients is important and may be cost 
effective even in spite of the high prices of modern im-
munomodulatory drugs, when taking into account the 
reduced quality of life and the enormous secondary costs 
due to disability. This in return has made it worthwhile 
for pharmaceutical companies to invest in the develop-
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established as effective therapy for several human auto-
immune conditions. Yet, for a number of reasons, they 
have remained a ‘second-line’ option for the treatment of 
relapsing-remitting MS.
 The remaining articles deal with recent developments 
of monoclonal antibody (mAb) therapies. mAbs, uni-
form in their molecular make-up, have defined specifici-
ties and are thought to constitute a particularly promis-
ing class of bioactive molecules. Traditionally, mAbs are 
generated from rodents after immunization with a target 
molecule of choice. B cells from immunized animals are 
immortalized by fusion with myeloma cells creating 
‘ hybridomas’, which are then cloned and tested for the 
specificity of their secreted antibodies  [1] . Using this ap-
proach, researchers have generated mAbs against a pleth-
ora of different target antigens, which now serve as ubiq-
uitous tools in research laboratories around the world. 
However, as therapeutic agents, common mAbs with a 
rodent molecular buildup have been shown to possess 
limited applicability in humans. Due to their structural 
differences to human antibodies they are – when injected 
repeatedly – recognized as foreign proteins and often 
neutralized by the recipient’s immune system. In order to 
circumvent this neutralizing immune response, biophar-
maceutical companies have undertaken great efforts to 
‘humanize’ rodent antibodies by using molecular tools: 
in a first step, immunoglobulin (Ig) variable genes from 
rodent hybridomas are fused with human IgG constant 
Table 1. Therapeutic antibodies in MS
Generic
name
Brand name Antibody type Target 
molecule
Target cell Stage of development for treating 
MS
IVIG several human, natural, polyclonal N/A N/A used as second-line treatment of MS
Natalizumab Tysabri humanized, recombinant, 
monoclonal
4-integrin activated lymphocytes licensed for treatment of MS
Alemtuzumab Campath-1H humanized, recombinant, 
monoclonal
CD52 T cells, B cells, mono-
cytes, macrophages
clinical trials
Daclizumab Zenapax humanized, recombinant, 
monoclonal
CD25 T cells clinical trials
Rituximab Rituxan chimeric, recombinant, 
monoclonal
CD20 B cells clinical trials
Infliximab Remicade chimeric, recombinant, 
monoclonal
TNF- N/A approved for the treatment of
rheumatoid arthritis; discontinued 
for the treatment of MS
CNTO-1275 N/A human, recombinant, 
monoclonal
IL-12/23 p40 N/A preclinical
ch5D12 N/A chimeric, recombinant, 
monoclonal
CD40 antigen-presenting
cells
preclinical
Overview of antibody-based therapeutics used or evaluated for the treatment of MS. IVIG = Intravenous immunoglobulins; N/A = 
not applicable; TNF- = tumor necrosis factor-; IL = interleukin.
Murine
100% mouse protein
Chimeric
33% mouse protein
CDR-grafted
5–10% mouse protein
UltiMAb antibodies
100% human protein
 Fig. 1. Recombinant techniques allow dif-
ferent extents of ‘humanization’ of mAbs 
(http://www.medarex.com/Development/
Evolution.htm). CDR = Complementarity 
determining regions. 
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region genes and expressed recombinantly as ‘chimeric’ 
antibodies. These antibodies are far less immunogenic, 
but can still elicit immune responses. Alternatively, the 
complementarity determining regions of the antibody, 
which are most relevant for the antigen recognition, can 
be grafted into a human IgG backbone, creating ‘human-
ized’ antibodies. Recent developments allow the genera-
tion of fully human mAbs by either using transgenic mice 
carrying human Ig genes  [2] or by cloning antibodies di-
rectly from the human immune repertoire  [3] . 
 In order to influence the immune system, mAbs can 
act by neutralizing soluble factors like cytokines, as in the 
case of infliximab or CNTO-1275 ( table 1 ). Alternatively, 
they can alter immune cell functions by binding to cell 
surface molecules, as in the case of natalizumab, dacli-
zumab and ch5D12. In contrast, alemtuzumab and ritux-
imab alter the function of the immune system by deplet-
ing whole subpopulations of immune cells. 
 In their article, Engelhardt and Kappos describe the 
preclinical and clinical development of natalizumab 
(Tysabri  ), which has recently been (re)licensed for the 
treatment of patients with severe forms of relapsing MS. 
Clinical trials have demonstrated that natalizumab is 
currently one of the most efficacious treatments for this 
type of MS. Natalizumab interferes with lymphocyte ex-
travasation, thus limiting their contribution to local in-
flammatory processes. To which extent the ‘beneficial 
immunosurveillance’ is affected as well has been under 
close observation since 3 patients developed progressive 
multifocal leukencephalopathy while being treated with 
natalizumab in combination with other agents influenc-
ing the immune system.
 Most of the other mAbs described in this issue of  Neu-
rodegenerative Diseases  are currently at different stages of 
preclinical or clinical development with regard to treat-
ing MS. Some of these mAbs, such as daclizumab, de-
scribed in the article by R. Martin, as well as rituximab 
and alemtuzumab, discussed by Jones and Coles, are al-
ready licensed for the treatment of certain types of hema-
tological malignancies. Infliximab, 1 of 3 currently avail-
able agents which neutralize the action of tumor necrosis 
factor-  , a key molecule in many inflammatory process-
es, is a very potent drug for the therapy of patients with 
severe forms of rheumatoid arthritis. Interestingly, al-
though tumor necrosis factor-  -neutralizing agents, 
elaborated by Taoufik and colleagues, also showed prom-
ising effects in a common animal model of MS, experi-
mental autoimmune encephalomyelitis, these agents 
completely failed in early trials with MS patients and ac-
tually increased disease activity. In their article, t’Hart 
and colleagues describe preclinical studies with mAbs in-
fluencing antigen presentation (CNTO-1275) and lym-
phocyte polarization (ch5D12).
 In summary, this issue of  Neurodegenerative Diseases 
emphasizes the enormous potential of antibody-based 
therapies for the treatment of MS and other immune-me-
diated diseases. However, even the selective targeting of 
a single immune-relevant molecule can apparently in-
duce effects completely unforeseeable in both animal 
models and patients with different diseases. Such unex-
pected adverse effects stress the need to further study 
both basic mechanisms of immunomodulation in con-
junction with well-conducted clinical trials.
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